Compare CLW & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLW | RPID |
|---|---|---|
| Founded | 1926 | 2006 |
| Country | United States | United States |
| Employees | 3710 | N/A |
| Industry | Paper | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.3M | 204.3M |
| IPO Year | 2008 | 2021 |
| Metric | CLW | RPID |
|---|---|---|
| Price | $14.50 | $2.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $22.67 | $8.00 |
| AVG Volume (30 Days) | 128.9K | ★ 196.4K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,555,400,000.00 | $33,587,000.00 |
| Revenue This Year | N/A | $19.12 |
| Revenue Next Year | $4.16 | $18.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.42 | ★ 19.74 |
| 52 Week Low | $12.46 | $2.01 |
| 52 Week High | $30.96 | $4.94 |
| Indicator | CLW | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 47.94 |
| Support Level | $12.46 | $2.36 |
| Resistance Level | $18.85 | $2.46 |
| Average True Range (ATR) | 0.59 | 0.14 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 25.30 | 81.11 |
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.